TrialWire™, the AI-powered clinical trial patient recruitment platform, today announced that CEO and Founder Susan Fitzpatrick-Napier will speak at Fierce Biotech Week at Encore Boston Harbor. TrialWire will detail how its platform finds the right people through algorithms mapped directly to a study's protocol, then applies AI precision screening so that only genuinely eligible candidates ever reach a site's portal for follow-up.

The message to sponsors, CROs and sites is deliberately counter to the recruitment industry's volume habit: sending more referrals is not the same as sending better ones, and every under-qualified referral costs a coordinator time they don't have.

Finding the right people, not just more people

TrialWire's algorithms identify people who are actively researching their condition and health options online and match them in real time to the therapeutic area of a live study. Rather than relying on static, often outdated databases, the platform engages candidates at the moment of intent and pulls approved eligibility and exclusion criteria from trial registries such as ClinicalTrials.gov.

Matched candidates are then invited into the platform's AI-Match screener, which evaluates each person against the study's inclusion/exclusion criteria before any referral is made. Only those who clear that bar are advanced.

Why “send only the best” is the whole point

The session will make the case that precision at the top of the funnel is what actually protects timelines at the bottom of it. When sites are flooded with poorly qualified referrals, study coordinators—who are often juggling multiple trials alongside routine patient care—burn hours chasing people who were never eligible. Candidates, meanwhile, are asked to invest their own time and hope in a trial they can't join.

TrialWire's approach is to advance only AI-screened, qualified, trial-ready candidates into each site's secure portal, delivered with the context coordinators need to move quickly to secondary screening. The result is less administrative drag on sites, a better experience for patients, and enrollment speed that holds up under real site conditions.

“Speed only matters if a site can absorb it. If we send a coordinator ten referrals and eight aren't eligible, we haven't helped the study—we've added work and lost days. Our job is to do the screening upstream, so that what lands in a site's portal is a short list of people who genuinely match the protocol and are ready to be evaluated. That respects the coordinator's time and the patient's time, and it's the fastest path to enrolling on schedule.”

— Susan Fitzpatrick-Napier, CEO & Founder, TrialWire

Built for the people who have to act on the referral

Every referral surfaces inside TrialWire's secure portal, built on Salesforce Health Cloud with role-based access so sponsors, CROs and site coordinators each see only what's relevant to them. Integrated communication tools help coordinators reach candidates quickly to confirm eligibility and book visits—closing the contact gaps where a large share of otherwise-eligible patients are typically lost. The platform is fully HIPAA and GDPR compliant.

About TrialWire™

TrialWire™ is an AI-powered clinical trial patient recruitment platform that helps sponsors and CROs accelerate enrollment by identifying and pre-screening motivated people who are actively seeking health information online. Rather than driving volume into sites, the platform advances only highly AI-screened, qualified participants who are ready for site evaluation—moving studies from approval to active screening in under 24 hours. Built on Salesforce Health Cloud and fully HIPAA and GDPR compliant, TrialWire operates globally with offices in San Francisco, Sydney, Singapore and Paris. Learn more at www.trial-wire.com.

Media Contact

TrialWire PR Team

Team@trial-wire.com

www.trial-wire.com

###